MedTrace Logo

A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma

NCT05764954 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-04-09

No results posted yet for this study

Summary

The researchers are doing this study to find out if treatment with TTFields using the NovoTTF-200T System is safe and practical (feasible) before surgical removal (resection) of lung adenocarcinoma (ADC). The researchers will also look at how the treatment may help the body's immune system to fight cancer.

Conditions

  • Adenocarcinoma of Lung

Interventions

DEVICE

NovoTTF-200T System

The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week).

Sponsors & Collaborators

Principal Investigators

  • Prasad Adusumilli, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-04
Primary Completion
2027-08-31
Completion
2027-08-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05764954 on ClinicalTrials.gov